经皮镇痛装置同步实现局麻药输注与周围神经电刺激的初步可行性研究
本研究为前瞻性试点病例系列,纳入20例择期行中度至重度疼痛的肩部或足踝手术成人患者,在超声引导下将集成导管与脉冲发生器的装置置入臂丛或坐骨神经旁,评估术后镇痛可行性与安全性。结果显示术后前7天日均疼痛评分中位数为2分,第一周羟考酮累积用量中位数为43 mg,装置成功实现单次局麻药推注、持续神经周围输注及电刺激。
要点
- 该装置可经超声引导经皮置入,同步完成单次阻滞、持续输注与神经电刺激。
- 术后前7天日均NRS中位数2分,第一周羟考酮累积用量中位数43 mg。
- 研究支持开展随机假对照临床试验进一步验证疗效。
核心结论
- 该新型装置成功实现了单次局麻药推注、持续神经周围输注以及同步或后续的电刺激。
- 研究认为有必要开展随机假对照临床试验。
研究设计与样本
- 前瞻性试点病例系列,在美国FDA研究性器械豁免下执行。
- 纳入20例择期行中度至重度疼痛的肩部或足踝日间手术成人患者。
- 装置在超声引导下置入臂丛或坐骨神经旁,术后第1-5、7、8、14天收集数据。
主要发现
- 术后前7天日均疼痛强度NRS中位数(IQR)为2(0,3)。
- 术后第1天之后,日均NRS和最大NRS分别低于2和5。
- 整个0-14天研究期间最严重疼痛:7例(35%)轻度(NRS<4),10例(50%)中度(NRS 4-7),3例(15%)重度(NRS>7)。
- 第一周羟考酮累积用量中位数为43(18,73)mg。
临床怎么用
- 该装置可在与传统单次神经阻滞相当的时间窗内置入,实现单次阻滞、持续输注和神经调控的一体化管理。
- 术后电刺激持续7天,装置可在患者家中移除。
局限性
- 本研究为试点可行性病例系列,样本量小(n=20),无对照组。
- 原文未报告随机对照或盲法设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A novel device integrating both local anesthetic delivery and peripheral nerve stimulation (PNS) to treat postoperative pain is under development. The device uses a catheter-over-needle design that permits ultrasound-guided percutaneous insertion. An integrated electrode and pulse generator enable PNS for up to 28 days. Such an approach may represent a paradigm shift in postoperative pain management by enabling the delivery of (1) a single-injection peripheral nerve block, (2) a continuous peripheral nerve block, and (3) neuromodulation-all through a single system that can be placed in a timeframe comparable with that of a traditional single-injection nerve block. The current prospective pilot study was executed under a US Food and Drug Investigational Device Exemption to develop insertion and management protocols, as well as assess the feasibility and safety of using the device to treat postoperative pain. METHODS: Preoperatively, adults (n=20) undergoing moderate-to-severely painful ambulatory shoulder or foot/ankle surgery had a device (RELAY, Gate Science, Moultonborough, NH) inserted under ultrasound guidance adjacent to the brachial plexus or sciatic nerve, respectively. Accurate insertion was confirmed with a 10 mL bolus of lidocaine via the catheter followed by bupivacaine (10 mL). If a continuous infusion was indicated, a portable pump was used to infuse ropivacaine (6-8 mL/h, 500 mL reservoir). Electric current was delivered using the integrated pulse generator for 7 days, followed by removal at home. Participants were contacted for data collection on postoperative days 1-5, 7, 8, and 14. RESULTS: During the first seven postoperative days, the median (IQR) "average" daily pain intensity as measured with the numeric rating scale (NRS) was 2 [0, 3]. Following postoperative day 1, daily average and maximum/worst NRS was less than 2 and 5, respectively. Regarding the "worst" (maximum) pain level over the entire study period of Days 0-14, 7 (35%) experienced mild pain (NRS<4), 10 (50%) moderate pain (NRS 4-7), and 3 (15%) severe pain (NRS>7). Cumulative oxycodone consumption the first week was a median of 43 (18, 73) mg. CONCLUSIONS: This novel device successfully delivered a single-injection local anesthetic bolus, a continuous perineural infusion, and concurrent/subsequent electrical current. A randomized, sham-controlled clinical trial appears warranted. CLINICALTRIALSGOV : NCT06818708.
引用
- Ilfeld BM, Said ET, Park BH, et al. Percutaneous analgesic device enabling both local anesthetic delivery and electrical stimulation (neuromodulation) of peripheral nerves: a pilot feasibility study (case series). Reg Anesth Pain Med. 2026. PMID: 41005804. doi:10.1136/rapm-2025-107029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。